The decreased miR-155 activity in NAFLD patients may be due to the adipogenic transcription factors CCAAT/enhancer binding protein (C/EBP)-α, C/EBP-β, PPAR-γ, and liver X receptor (LXRα) [52]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.